Rhus coriaria L. increases serum apolipoprotein-A1 and high-density lipoprotein cholesterol levels： a double-blind placebo-controlled randomized clinical trial  

作　　者：Zahra Hajmohammadi Mojtaba Heydari Majid Nimrouzi Pouya Faridi Mohammad Javad Zibaeenezhad Gholamhossein Ranjbar Omrani Mesbah Shams 

机构地区：[1]Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz 98713, Iran [2]Department of Traditional Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz 98713, Iran [3]Department of Phytopharmaceuticals, School of Pharmacy and Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran [4]Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran [5]Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran

出　　处：《Journal of Integrative Medicine》2018年第1期45-50,共6页结合医学学报（英文版）

基　　金：supported by a grant from Shiraz University of Medical Sciences–Iran (Grant No. 92-5581)

摘　　要：Background： Lipid-lowering effect ofRhus coriaria L. （Rhus） has been investigated in multiple animal stud- ies with promising results. Nonetheless, its clinical efficacy has not been adequately examined. Objective： The aim of this study was to evaluate the lipid-lowering effects of Rhus among patients with hyperlipidemia. Design, setting, participants and interventions： The study was designed as a two-arm, double-blind placebo-controlled randomized clinical trial, using a parallel design. Eighty patients with primary hyper- lipidemia were randomly assigned to receive Rhus capsules or placebo for 6 weeks. Main outcome measures： The serum lipid levels, apolipoprotein-A1 （Apo-A1） and apolipoprotein-B （Apo-B） were measured. Results： Mean serum high-density lipoprotein cholesterol （HDL-C） and Apo-Al levels were significantly increased in the Rhus group, compared with the placebo group, after 6 weeks of intervention （P= 0.001）. The analysis of covariance test including age, gender, body mass index （BMI）, and smoking as co-variables revealed that the increase in HDL-C and Apo-A1 levels remained significant, and increases in HDL-C were dependent on the increase in Apo-A1 levels. No significant difference was observed between Rhus and placebo groups in terms of mean reductions in total cholesterol, low-density lipopro- tein cholesterol and triglyceride levels; however, more significant improvement was observed among obese patients （BMI≥ 30 kg/m^2）. Conclusion： The study showed significant increases in HDL-C and Apo-Al levels in response to Rhus sup- plementation in patients with hyperlipidemia. Trial registration： ClinicalTrials.gov ID： NCT02295293.Background： Lipid-lowering effect ofRhus coriaria L. （Rhus） has been investigated in multiple animal stud- ies with promising results. Nonetheless, its clinical efficacy has not been adequately examined. Objective： The aim of this study was to evaluate the lipid-lowering effects of Rhus among patients with hyperlipidemia. Design, setting, participants and interventions： The study was designed as a two-arm, double-blind placebo-controlled randomized clinical trial, using a parallel design. Eighty patients with primary hyper- lipidemia were randomly assigned to receive Rhus capsules or placebo for 6 weeks. Main outcome measures： The serum lipid levels, apolipoprotein-A1 （Apo-A1） and apolipoprotein-B （Apo-B） were measured. Results： Mean serum high-density lipoprotein cholesterol （HDL-C） and Apo-Al levels were significantly increased in the Rhus group, compared with the placebo group, after 6 weeks of intervention （P= 0.001）. The analysis of covariance test including age, gender, body mass index （BMI）, and smoking as co-variables revealed that the increase in HDL-C and Apo-A1 levels remained significant, and increases in HDL-C were dependent on the increase in Apo-A1 levels. No significant difference was observed between Rhus and placebo groups in terms of mean reductions in total cholesterol, low-density lipopro- tein cholesterol and triglyceride levels; however, more significant improvement was observed among obese patients （BMI≥ 30 kg/m^2）. Conclusion： The study showed significant increases in HDL-C and Apo-Al levels in response to Rhus sup- plementation in patients with hyperlipidemia. Trial registration： ClinicalTrials.gov ID： NCT02295293.

关 键 词：Dyslipidemias Rhus coriaria LLipids Dietary supplements Plants Apolipoproteins A Randomized controlled trial Double-blind method 

分 类 号：R1[医药卫生—公共卫生与预防医学]